US 11,807,689 B1
Anti-CD20 antibody compositions
George Costas Avgerinos, Sudbury, MA (US); Patrick Michael Hossler, Westborough, MA (US); Jill A. Myers, Brookline, MA (US); and Yune Z. Kunes, Cambridge, MA (US)
Assigned to TG Therapeutics, Inc., New York, NY (US); and Laboratoire Francais du Fractionnement et des Biotechnologies, Les Ulis (FR)
Filed by TG Therapeutics, Inc., New York, NY (US); and Laboratoire Francais Du Fractionnement Et Des Biotechnologies, Les Ulis (FR)
Filed on Aug. 22, 2022, as Appl. No. 17/892,465.
Claims priority of provisional application 63/347,852, filed on Jun. 1, 2022.
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 47/02 (2006.01)
CPC C07K 16/2887 (2013.01) [A61K 47/02 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01)] 22 Claims
 
1. A pharmaceutical formulation comprising a composition comprising a population of anti-CD20 antibody proteins, wherein the anti-CD20 antibody proteins in the population are expressed from one or more nucleic acid sequences encoding a heavy chain comprising the amino acid sequence of SEQ ID NO:1 and a light chain comprising the amino acid sequence of SEQ ID NO:2, wherein the population of anti-CD20 antibody proteins has an N-glycan profile comprising 10 to 20% galactosylated glycans and 20 to 40% fucosylated glycans, wherein the anti-CD20 antibody proteins are present in the pharmaceutical formulation at a concentration of 10 mg/mL to 50 mg/mL.